← All trials
NCT03769155
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 13, 2018
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2031
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Emory UniversityLead sponsor
- Emory UniversityOverall official - principal investigator
- Emory UniversityReponsible party - principal investigator
- National Cancer Institute (NCI)Collaborator
- National Institutes of Health (NIH)Collaborator
- Vaccinex Inc.Collaborator
- Emory UniversityOfficial
- Bristol-Myers SquibbCollaborator
- Emory UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.